POLYMORPHIC α-ADDUCTIN(ADD1) GENE OPTIONS ASSOCIATED WITH CARDIOVASCULAR PATHOLOGY

Modern approaches to drug therapy should be based not only on effectiveness, but also on a comprehensive assessment of the safety of drugs. Pharmakogenetic testing allows to define efficiency and safety of therapy, to choose the most effective medicine as prime therapeutic means that leads to reduction of quantity of the medical products necessary for adequate treatment. At present, advances in clinical genetics are associated with the isolation of alleles (variants) of various genes, the assessment of their frequency and the detection of associations of certain alleles with phenotypic manifestations, with an attempt to identify prognostic signs. On the basis of complex pharmakogenetic analysis is possible to identify significant of genetic markers in the prediction of the flow and effectiveness of pharma-cotherapy of arterial hypertension. The study involved 40 of patients with arterial hypertension. Performed pharmakogenetic testing with the study of polymorphisms of gene α-adductin. As a result of which it was possible to obtain results: “normal” alleles of the α-adductin G / G gene were found in the majority of the studied (29 out of 40 patients), while the “risk” allele of the α-adductin G / T gene and the “risk” allele T / T - in 11 studied patients, and the frequency of occurrence of the G / T allele is 4 times greater than the T / T allele. The identification of genetic markers in cardiology is subjected to intensive study and research in order to identify genetic risk. Thus,оn the basis of the results of genetic testing can not only build the forecast of disease, but also rationally choose the drug therapy, which helps to prevent the development of severe complications.

polymorphisms of genes, arterial hypertension, pharmacogenetic analysis, genotyping, prediction, α-adductin